Expand XENE Menu
XENE MENU

XENE Latest Press Releases

-- August 28, 2026 --

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:01 PM

-- August 26, 2026 --

Xenon to Highlight Phase 3 X-TOLE2 Clinical Data and Rational Polytherapy Potential for Azetukalner at EEC 2026 Globe Newswire 4:01 PM

-- August 6, 2026 --

Xenon Reports Q2 2026 Financial Results and Provides Business Update Globe Newswire 4:01 PM

-- July 31, 2026 --

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:01 PM

-- July 30, 2026 --

Xenon to Report Q2 2026 Financial Results on August 6, 2026 Globe Newswire 4:01 PM

-- July 2, 2026 --

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:01 PM

-- May 29, 2026 --

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:01 PM

-- May 7, 2026 --

Xenon Reports Q1 2026 Financial Results and Provides Business Update Globe Newswire 4:01 PM

-- May 1, 2026 --

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:01 PM

-- April 30, 2026 --

Xenon to Report Q1 2026 Financial Results on May 7, 2026 Globe Newswire 4:01 PM

-- April 19, 2026 --

Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting Globe Newswire 6:00 PM

-- April 15, 2026 --

Xenon to Present at Upcoming Investor Conferences Globe Newswire 8:30 AM

-- April 7, 2026 --

Xenon to Highlight Phase 3 X-TOLE2 & Long-Term Data for Azetukalner in Focal Onset Seizures at 2026 AAN Annual Meeting Globe Newswire 8:30 AM
Market Data Delayed 15 Minutes